World Trade Center Attack and Cardiac Events: Fact or Fear?  by Fauchier, Laurent et al.
The Optimal Low-Density
Lipoprotein Is 50 to 70 mg/dl
It was with great delight that I read the report by O’Keefe et al. (1)
in a recent issue of the Journal. It provides scientific support to my
practice decisions over the last six years. I have been treating
virtually all of my patients over 40 years of age to reduce their
low-density lipoprotein (LDL) cholesterol to 2.0 mmol/l (77
mg/dl) with a target of 1.5 mmol/l (58 mg/dl).
I am a general practitioner in Sudbury, Ontario, which is a
cardiovascular “hotspot” owing both to the genetics in the Fran-
cophone population, and our high rate of smoking and obesity.
The average age of my patients is in the 60s. At last count, I had
186 patients with type II diabetes, and the usual number of
smokers, hypertensive, sedentary life-style and obese patients;
overall, a higher than average risk practice.
Since reading in 1998 that the average myocardial infarction
(MI) patient in our part of Canada has only 1.8 cardiovascular risk
factors, it has become quite clear to me that the only common
denominator in an acute coronary syndrome (ACS), or thrombotic
cerebral vascular accident (CVA), in my practice was an LDL of
2.0.
Hence, I have been very aggressive with LDL lowering in my
patient group. As a consequence, the rate of MIs in my 3000-
patient general practice has gone from 50 to 60 per year to 2 per
year. I have had only a single ACS in my treated and compliant
populace since 1998. This was in a woman with six of seven coronary
heart disease risk factors; she began treatment in December 2000
and suffered (and survived) an ACS three months later. In the
same period of time, I have had eight other ACS events in patients
and one thrombotic CVA, all of which were in noncompliant
patients.
It has been my practice to screen all patients over age 40 and
patients in their 30s with significant family history of premature
MI or a significant number of risk factors. My impression is that
there is a “cut-off” level of the LDL below which the atheroscle-
rotic process is halted, and indeed reversed by the documented
function of high-density lipoprotein (HDL) in reabsorbing estab-
lished plaque. It seems as though LDL is a necessary ingredient in
the atherosclerotic process, in whose absence the other cardiovas-
cular risk factors are unable to exert influence in accelerating the
process.
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REPLY
We thank Dr. Clendenning for his interest in our study (1). Dr.
Clendenning’s suggestion that the systematic treatment of his
patients to a low-density lipoprotein (LDL) cholesterol target of
2.0 mmol/l (77 mg/dl) over the past four years has markedly
reduced cardiovascular event rate in his practice is fascinating and
consistent with the hypothesis of our study. Several other physi-
cians have communicated similar experiences to us that provide
anecdotal support for the concept that the optimal LDL range for
patients at risk for cardiovascular event is 50 to 70 mg/dl. One solo
practitioner cardiologist from Idaho who has employed a similar
strategy targeting the LDL to 70 mg/dl as part of a multimodal
risk-factor intervention recently decided to stop performing per-
cutaneous coronary interventions because he believed his volume of
procedures has dropped too low to maintain adequate skills.
Aggressive LDL lowering has been shown to improve prognosis
even in patients without coronary heart disease (CHD) who have
average LDL levels at baseline, but who have CHD risks such as
hypertension (2), diabetes (3), or low HDL cholesterol levels (4).
This accumulating evidence suggests that achieving these lower
LDL targets will improve CHD prognosis for many of our
patients.
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World Trade Center Attack
and Cardiac Events: Fact or Fear?
The Journal recently published two studies suggesting a specific
increase in the number of ventricular arrhythmias in implantable
defibrillator patients in the weeks following the World Trade
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Center (WTC) attack of September 11, 2001 (9/11), both in
patients living near or geographically distant from New York City
(1,2). By contrast, another work found that, compared with control
years, there was no disproportionate increase in cardiovascular
mortality after the terrorist attacks in New York City (3). A major
advantage of this latter study is to compare the variation in the
occurrence of events in 2001 and in the years since 1997 (an
analysis of “the variation of the variations”).
We believe interpretation of the results of Steinberg et al. (1)
and of Shedd et al. (2) might therefore be doubtful. Similarly, if
the investigators had also found that arrhythmic events were more
frequent on 9/11 between 9 AM and 12 noon (after the attack) than
between 5 AM and 8 AM (before the attack), it would be difficult to
make a direct relation between this phenomenon and the attack,
because there is a well-known diurnal variation of cardiac events,
with more frequent events in the morning hours (4).
Because a circannual variation of malignant ventricular tachy-
arrhythmias in patients with implantable cardioverter-defibrillators
has clearly been reported (with a lower number of events in
summer than in autumn and winter) (5), we believe the analysis of
the variation of events across several years would also be mandatory
to conclude that the WTC tragedy was associated with an
increased risk of life-threatening ventricular arrhythmias in the
general population.
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REPLY
We appreciate the comments of Dr. Fauchier and colleagues
regarding our recent reports describing an increase in the incidence
of life-threatening ventricular arrhythmias in both New York City
(1) and Florida (2) in the aftermath of the World Trade Center
(WTC) attack.
A concern was raised that we did not compare the event rate of
2001 with a control period. In fact, we did compare the 30-day
period following September 2001 with 13 monthly periods after-
ward (including September 2002) and found the index month to
have a statistically higher arrhythmia event rate, with an odds ratio
of 2.5 (p 0.004) than all other monthly intervals (1). Thus, there
appeared to be a specific aberration temporally linked to the period
following the WTC attack, which was not attributable to seasonal
or monthly variation. We also noted that the study of cardiovas-
cular mortality in New York City (3) did not confirm a higher
death rate, but this form of analysis, using death certificates, is
fraught with inaccuracies in assessment of cause of death that may
make it insensitive for evaluating specific arrhythmic events.
Fauchier et al. state that if the events had concentrated in the
morning hours after the attack on September 11, this would lend
credence to our conclusions. However, as described (1), the event
rate did not increase on September 11, but did increase three days
later, and remained elevated for one month. In respect to the
diurnal variation of events, we surprisingly found a shift in the
preponderance of events to the evening instead of the morning
(J.S. Steinberg, unpublished observations, 2001), supporting spec-
ulation that stress was heightened by exposure to the graphic
scenes replayed by the media (1).
*Jonathan S. Steinberg, MD, FACC
Aysha Arshad, MBBS
Alan Rozanski, MD, FACC
Omer L. Shedd, MD
Anne B. Curtis, MD, FACC
*Division of Cardiology
St. Luke’s–Roosevelt Hospital Center
1111 Amsterdam Avenue
New York, NY 10025
E-mail: jss7@columbia.edu
doi:10.1016/j.jacc.2005.02.042
REFERENCES
1. Steinberg JS, Arshad A, Kowalski M, et al. Increased incidence of
life-threatening ventricular arrhythmias in implantable defibrillator
patients after the World Trade Center attack. J Am Coll Cardiol
2004;44:1261–4.
2. Shedd OL, Sears SF Jr., Harvill JL, et al. The World Trade Center
attack: increased frequency of defibrillator shocks for ventricular ar-
rhythmias in patients living remotely from New York City. J Am Coll
Cardiol 2004;44:1265–7.
3. Chi JS, Poole WK, Kandefer SC, Kloner RA. Cardiovascular mortality
in New York City after September 11, 2001. Am J Cardiol
2003;92:857–61.
Improved Outcomes of Pediatric Dilated
Cardiomyopathy and Heart Transplantation
The report by Tsirka et al. (1) provided a very useful update of the
outcomes for infants and children who develop dilated cardiomy-
opathy (DCM). Their use of a category combining death and
cardiac transplant (“heart death”) as end points was sensible and
helpful. However, some of the diagnostic categories were less than
fully explained and somewhat arbitrary. If patients with muscular
dystrophy (n  4) and inherited metabolic disorders (n  5), both
uniformly fatal diseases, were not included, their total population
of DCM would be only 82 instead of 91, and the population of
survivors with recovery of normal contractility would amount to
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